J. Goldman & CO LP Eagle Pharmaceuticals, Inc. Transaction History
J. Goldman & CO LP
- $3.21 Billion
- Q3 2024
A detailed history of J. Goldman & CO LP transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 150,611 shares of EGRX stock, worth $97,897. This represents 0.02% of its overall portfolio holdings.
Number of Shares
150,611
Previous 191,111
21.19%
Holding current value
$97,897
Previous $1.07 Million
47.85%
% of portfolio
0.02%
Previous 0.03%
Shares
7 transactions
Others Institutions Holding EGRX
# of Institutions
70Shares Held
8.6MCall Options Held
1MPut Options Held
100-
Nantahala Capital Management, LLC New Canaan, CT2.36MShares$1.53 Million0.52% of portfolio
-
Aigh Capital Management LLC Baltimore, MD1.21MShares$787,4801.82% of portfolio
-
Citigroup Inc1MShares$650,2520.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA580KShares$376,6790.0% of portfolio
-
Aqr Capital Management LLC Greenwich, CT375KShares$243,7440.0% of portfolio
About EAGLE PHARMACEUTICALS, INC.
- Ticker EGRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 13,015,900
- Market Cap $8.46M
- Description
- Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...